Evidence map›Paper›PMID 33329550›Full record

ArticleFrontiers in immunology2020

CD4

Kutaiba Alhaj Hussen, David Michonneau, Vincent Biajoux, Seydou Keita, Laetitia Dubouchet, Elisabeth Nelson, Niclas Setterblad, Helene Le Buanec, Jean-David Bouaziz, Fabien Guimiot and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Kutaiba Alhaj HussenINSERM U976, Université de Paris, École Pratique des Hautes Études/PSL Research University, Institut de Recherche Saint Louis, Paris, France.
David MichonneauINSERM U976, Université de Paris; Service d'hématologie-greffe, AP-HP, Hôpital Saint-Louis, Institut de Recherche Saint Louis, Paris, France.
Vincent BiajouxINSERM U976, Université de Paris, École Pratique des Hautes Études/PSL Research University, Institut de Recherche Saint Louis, Paris, France.
Seydou KeitaINSERM U976, Université de Paris, École Pratique des Hautes Études/PSL Research University, Institut de Recherche Saint Louis, Paris, France.
Laetitia DubouchetINSERM U976, Université de Paris; Service d'hématologie-greffe, AP-HP, Hôpital Saint-Louis, Institut de Recherche Saint Louis, Paris, France.
Elisabeth NelsonINSERM U976, Université de Paris, École Pratique des Hautes Études/PSL Research University, Institut de Recherche Saint Louis, Paris, France.
Niclas SetterbladPlateforme d'Imagerie et de Tri Cellulaire, Institut de Recherche Saint Louis, Paris, France.
Helene Le BuanecINSERM U976, Dermatology Department, Hôpital Saint-Louis, Institut de Recherche Saint Louis, Paris, France.
Jean-David BouazizINSERM U976, Dermatology Department, Hôpital Saint-Louis, Institut de Recherche Saint Louis, Paris, France.
Fabien GuimiotINSERM UMR 1141, Service de Biologie du Développement, Université de Paris, Hôpital Robert-Debré, AP-HP, Paris, France.
Gérard SociéINSERM U976, Université de Paris; Service d'hématologie-greffe, AP-HP, Hôpital Saint-Louis, Institut de Recherche Saint Louis, Paris, France.
Bruno CanqueINSERM U976, Université de Paris, École Pratique des Hautes Études/PSL Research University, Institut de Recherche Saint Louis, Paris, France.
Hôpital Saint-Louis · FRInstitut de recherche Saint-Louis · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRÉcole Pratique des Hautes Études · FRHIPI - Immunologie humaine, physiopathologie et immunithérapie · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mechanisms driving acute graft-versus-host disease (aGVHD) onset in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) are still poorly understood. To provide a detailed characterization of tissue-infiltrating T lymphocytes (TL) and search for eventual site-specific specificities, we developed a xenogeneic model of aGVHD in immunodeficient mice. Phenotypic characterization of xenoreactive T lymphocytes (TL) in diseased mice disclosed a massive infiltration of GVHD target organs by an original CD4

Indexed as

Hematopoietic Stem Cell TransplantationAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesFemaleGraft vs Host DiseaseHumansImmunologic MemoryMaleMiceMice, SCIDProgrammed Cell Death 1 ReceptorT-Lymphocytes, CytotoxicTransplantation, HeterologousCytokinesProgrammed Cell Death 1 Receptorallogeneic hematopoietic stem cell transplantationCD4+CD8+ T lymphocytesgraft-versus-host diseaseimmunoregulatory diversionxenograft mouse model

Identifiers

PMID33329550
PMCPMC7732609
OpenAlexW3107081283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.